Trial · NCT02927080
Participant flow40
How many started, completed or left each group, period by period.
1 to 20 of 40
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | ACE-083 (Part 1, Cohort 1a) Tibialis Anterior (TA) Unilateral | 6 | |
| Overall Study | STARTED | ACE-083 (Part 1, Cohort 2a) Tibialis Anterior (TA) Unilateral | 6 | |
| Overall Study | STARTED | ACE-083 (Part 1, Cohort 3a) Tibialis Anterior (TA) Bilateral | 6 | |
| Overall Study | STARTED | ACE-083 (Part 1, Cohort 1b) Biceps Brachii (BB) Unilateral | 6 | |
| Overall Study | STARTED | ACE-083 (Part 1, Cohort 2b) Biceps Brachii (BB) Unilateral | 7 | |
| Overall Study | STARTED | ACE-083 (Part 1, Cohort 3b) Biceps Brachii (BB) Unilateral | 6 | |
| Overall Study | STARTED | Placebo (Part 2, DB-PC) Tibialis Anterior (TA) | 15 | |
| Overall Study | STARTED | ACE-083 (Part 2, DB-PC) Tibialis Anterior (TA) 240 mg | 14 | |
| Overall Study | STARTED | Placebo (Part 2, DB-PC) Biceps Brachii (BB) | 15 | |
| Overall Study | STARTED | ACE-083 (Part 2, DB-PC) Biceps Brachii (BB) 240 mg | 14 | |
| Overall Study | Open-Label Extension From Part 2 Double Blind-Placebo Controlled | ACE-083 (Part 1, Cohort 1a) Tibialis Anterior (TA) Unilateral | 0 | |
| Overall Study | Open-Label Extension From Part 2 Double Blind-Placebo Controlled | ACE-083 (Part 1, Cohort 2a) Tibialis Anterior (TA) Unilateral | 0 | |
| Overall Study | Open-Label Extension From Part 2 Double Blind-Placebo Controlled | ACE-083 (Part 1, Cohort 3a) Tibialis Anterior (TA) Bilateral | 0 | |
| Overall Study | Open-Label Extension From Part 2 Double Blind-Placebo Controlled | ACE-083 (Part 1, Cohort 1b) Biceps Brachii (BB) Unilateral | 0 | |
| Overall Study | Open-Label Extension From Part 2 Double Blind-Placebo Controlled | ACE-083 (Part 1, Cohort 2b) Biceps Brachii (BB) Unilateral | 0 | |
| Overall Study | Open-Label Extension From Part 2 Double Blind-Placebo Controlled | ACE-083 (Part 1, Cohort 3b) Biceps Brachii (BB) Unilateral | 0 | |
| Overall Study | Open-Label Extension From Part 2 Double Blind-Placebo Controlled | Placebo (Part 2, DB-PC) Tibialis Anterior (TA) | 14 | |
| Overall Study | Open-Label Extension From Part 2 Double Blind-Placebo Controlled | ACE-083 (Part 2, DB-PC) Tibialis Anterior (TA) 240 mg | 13 | |
| Overall Study | Open-Label Extension From Part 2 Double Blind-Placebo Controlled | Placebo (Part 2, DB-PC) Biceps Brachii (BB) | 14 | |
| Overall Study | Open-Label Extension From Part 2 Double Blind-Placebo Controlled | ACE-083 (Part 2, DB-PC) Biceps Brachii (BB) 240 mg | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02927080/flow